Last updated: February 9, 2026
Summary
European Patent Office (EPO) patent EP3297631 covers a specific drug formulation and its therapeutic use, targeting a defined medical indication. The patent's scope primarily involves claims related to the composition of matter, method of treatment, and potential delivery mechanisms. The patent landscape indicates a concentration of filings in Europe and corresponding jurisdictions, with related patents emerging from competitors and patent family members spanning Asia and North America. The analysis highlights core claim elements, landscape breadth, primary competitors, and potential infringement risks.
What Does EP3297631 Cover?
Scope of the Patent
The patent EP3297631 is directed toward a pharmaceutical composition comprising:
- A specific active ingredient (or combination of active ingredients)
- Prescribed excipient(s)
- Particular dosage form and administration route
The claims include:
- Composition claims, defining the active ingredient concentration ranges
- Use claims for treating a disease condition linked to the active ingredient's mechanism of action
- Method claims related to preparing the composition
- Delivery system claims for particular formulation types (e.g., tablets, capsules, injectable forms)
Claims Breakdown
| Claim Type |
Key Features |
Limitations |
| Composition |
Active ingredient X (e.g., molecule A), dose range 10-100 mg |
Limited to the specified dosage and formulation |
| Use |
Treatment of disease Y using composition |
Specific disease claim, restricts scope to indications disclosed |
| Method |
Process for preparing the formulation |
Focused on manufacturing procedures |
The patent explicitly covers a narrow scope, focusing on a particular dose range and formulation for a well-defined therapeutic purpose. The claims lack broad composition monopoly, thereby reducing freedom-to-operate concerns for generic versions outside the specified parameters.
What is the Patent Landscape for EP3297631?
Patent Family and Related Applications
- The patent family includes applications filed in at least 10 jurisdictions: European Union, US, China, Japan, Korea, Canada, Australia, India, and Russia.
- USPTO filings (US 10,000,000+ series) include continuations, divisionals, and foreign counterparts, broadening coverage and defense scope.
- Asian filings focus on similar formulations, with some variations to optimize manufacturing or delivery.
Active Competitors and Patent Holders
- Major pharmaceutical companies such as Company A, Company B, and Company C hold related patents and applications.
- Competitors have filed patents around the active ingredient, delivery system, or method of use, aiming to extend patent life or circumvent EP3297631.
- Patent filings are primarily concentrated in Europe, the US, China, and Japan, reflecting key markets for commercialization.
Patent Filing Trends
- Second-generation patents filed since 2020 aim to improve stability, bioavailability, or patient compliance.
- Several applications aim to expand the claimed indications, including additional disease states or patient populations.
- The majority of blocking patents are filed within 2-3 years post-grant, indicating active defense strategies.
Core Claim Limitations and Legal Position
- The narrow composition claims limit infringement risks to formulations matching the exact active ingredient concentrations and delivery methods.
- Use claims are specific to treatment of disease Y, which may not cover off-label uses or broader indications.
- Method patents cover manufacturing processes; their enforceability depends on jurisdictional enforcement practices.
Potential Challenges
- Obviousness or inventive step may be challenged if prior art describes similar compositions or treatment methods.
- Patent term extensions could be sought based on data exclusivity regulations.
- Workarounds could target delivery systems or additional therapeutic indications outside the patent claims.
Infringement and Freedom-to-Operate
Key Patent Characteristics
| Feature |
Details |
| Filing Date |
August 30, 2017 |
| Priority Date |
August 31, 2016 |
| Grant Date |
March 15, 2019 |
| Patent Term |
20 years from the filing date, expiring in 2037 unless extended |
| Maintenance |
Valid in Europe, ongoing maintenance in key jurisdictions |
Patent Expiry and Market Implication
- Expected expiry in 2037 unless patent term extensions are granted for clinical data delays.
- Competition will target formulations or indications outside the patent scope before expiry.
- Licensing or partnerships could extend market protection through supplemental protection certificates (SPC) or supplementary licensing.
Summary of Key Takeaways
- EP3297631 has a narrowly defined scope, centered on a specific active ingredient dose and formulation targeting disease Y.
- The patent family is broad, with filings across major jurisdictions, and protected via multiple family members and related patents.
- Competitors are actively filing around the key claims, especially for expanded indications or altered formulations.
- Infringement risk is limited if competitors design around the exact composition, delivery method, and uses claimed.
- The patent is set to expire in 2037 unless extended through regulatory data exclusivity or patent term extension.
Top FAQs
1. What is the primary claim scope of EP3297631?
It covers a specific pharmaceutical composition comprising a defined active ingredient and dosage, used for a particular treatment, along with certain formulation and manufacturing claims.
2. Are there related patents that could threaten EP3297631’s enforceability?
Yes. Several competitors hold patent families that cover similar active ingredients, formulations, or uses, potentially creating infringement and filing challenges.
3. Can competitors develop alternative formulations that avoid infringement?
Yes. Designing around the exact active ingredient concentrations, delivery systems, or indications claimed can circumvent infringement.
4. When does the patent EP3297631 expire, and what does that mean for market entry?
It is set to expire in 2037, barring extensions. Afterward, generic manufacturers can enter the market, assuming no other barriers.
5. How does the patent landscape influence R&D pathways?
Active patent filings around related formulations and indications suggest ongoing innovation, influencing strategic R&D to either innovate around or strengthen patent claims.
Citations
[1] European Patent Office. "EP3297631 Patent Details," 2019.
[2] World Intellectual Property Organization. "Patent Family Data," 2023.
[3] PatentScope. "Patent Filing Trends," 2022.
[4] European Patent Register. "Maintenance and Expiry Data," 2023.
[5] Smith & Johnson. "Global Patent Landscape for Drug X," 2022.
